RepRegen™ Ltd. (Formerly Known as BioCeramic Therapeutics) Discloses Six-Month in Vivo Data Confirming Bone-Regeneration Properties of Stronbone(TM) Bone Graft Substitute - the First Product from the Company’s Platform to Repair and Regenerate Hard Tissue

LONDON--(BUSINESS WIRE)--RepRegen™, the ‘smart biomaterials’ company, announced today that three- and six-month data from an in vivo study of its CE-marked StronBone™ Bone Graft Substitute with Strontium demonstrated by analytical testing that it can generate bone quality in, and around, bone defects that is significantly superior to a standard bone void filler (TCP-CaSO4) in the control defect.